Xu
Xu v. FibroGen, Inc.
Opinion
Trial Court Opinion
UNITED STATES DISTRICT COURT NORTHERN DISTRICT OF CALIFORNIA 6 PEIFA XU, Case No. 21-cv-02623-EMC
Plaintiff,
ORDER GRANTING MOTIONS TO
v. CONSOLIDATE; AND GRANTING
RETIREMENT SYSTEMS’ MOTIONS
FIBROGEN, INC., et al., FOR APPOINTMENT AS LEAD
PLAINTIFF AND APPROVAL OF
Defendants. LEAD COUNSEL
Docket Nos. 22, 29,
13 I. INTRODUCTION This case is a securities-fraud class action brought on behalf of investors who purchased stock in FibroGen, Inc., from October 2017 through April 2021. Plaintiffs assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) as well as Securities and Exchange (“SEC”) Rule 10b-5. Pending before the Court are three class members’ motions for consolidation of related actions, appointment as lead plaintiff, and approval of lead counsel pursuant to the Private Securities Litigation Reform Act of 1995 (“PSLRA”). The motions were…